Delivery Order SPE2DB22D9239-SPE2DB24FDJ88

Award Date 5/23/24
Potential Completion Date 6/14/24
Potential Value $80K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4,563,469,465 units of the pharmaceutical product KEYTRUDA 100 MG/4 ML VIAL 4ML. The contract has a completion date of February 12, 2024 and a potential value of $80,218.40. This delivery order is part of a larger indefinite delivery contract held by DMS Pharmaceutical Group with DLA to provide various pharmaceutical and medical supplies...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $48,131.04 contract is to provide Keytruda 100 mg/4 ml vials to support the recurring medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide KEYTRUDA 100 MG/4 ML VIAL 4ML. The order has a potential value of $80,285.70 and a completion date of February 8, 2024. DMS Pharmaceutical Group Inc. holds an indefinite delivery contract with DLA to supply a variety of pharmaceutical and medical products to support military treatment facilities globally. This specific order is delivered under...
The U.S. Defense Logistics Agency Troop Support Medical awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Keytruda 100 mg/4 ml vials. The award, valued at $51,829.00, is part of a larger indefinite delivery contract (DLA contract 4600082013 under the SPE2DB program) with DMS Pharmaceutical Group that has a total potential value up to $4,999,999 through 2025. This contract vehicle enables the DLA to issue delivery orders...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $80,285.70, is for the delivery of 4,566,364,793 units of Keytruda 100 mg/4 ml vial (4 ml) to support the recurring medical supply needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC)...
The Defense Logistics Agency awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4,563,188,063 units of the pharmaceutical drug KEYTRUDA 100 MG/4 ML VIAL 4ML. The delivery order has a potential value of $155,010.40 and is set to be completed by January 18, 2024. DMS Pharmaceutical Group Inc. holds multiple indefinite delivery contracts with the Defense Logistics Agency to supply a variety of pharmaceutical and medical products in...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Keytruda 100 mg/4 ml vials. The contract has a potential value of $40,109.20 and a completion date of March 11, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 with DLA, which enables the agency to order a broad range of pharmaceutical products to support...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Keytruda (pembrolizumab) 100 mg/4 mL vials. The contract, valued at $80,218.40, has an ultimate completion date of October 9, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and DLA under the SPE2DB program, which has a ceiling value...
The U.S. government agency Medical Supply Chain, part of the Department of Defense, awarded a delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Keytruda 100 mg/4 ml vial. The fixed-price contract is valued at $80,285.70 and has a term ending on March 29, 2024. This award is associated with a larger indefinite delivery contract (SPE2DB) that DMS Pharmaceutical Group holds with the Defense Logistics Agency, valued at up to $4,999,999...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $40,142.85 firm fixed-price contract is for the supply of Keytruda 100 mg/4 ml vial. The contract has an ultimate completion date of July 3, 2024. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which allows the agency to...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB24FDJ88
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide 4,564,751,606 units of Keytruda 100 mg/4 mL vial. The firm-fixed-price contract, valued at $80,218.40, runs through June 14, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued at up to $499,999,999, which was awarded by the DLA to fulfill the recurring pharmaceutical supply needs of military health facilities worldwide. The contract has no set-aside designation.

Generated 8/22/24, 2:56 PM